OBJECTIVES: To determine which older adults tend to receive potentially inappropriate medications (PIMs), how this may differ according to cognitive status, and how the trajectories of PIM use change over time. DESIGN: Ten-year longitudinal cohort study. SETTING: Three clinical sites in the United States. PARTICIPANTS: One thousand four hundred eighty-four community-dwelling women aged 75 and older. MEASUREMENTS: At follow-up, cognitive status was ascertained and classified as normal, mild cognitive impairment (MCI), or dementia. Beers 2003 criteria and other literature were used to identify PIMs from detailed medication inventory performed at three time points. Anticholinergic load was measured using the Anticholinergic Cognitive Burden Scale (ACB), which assigns medications a value from 0 to 3 depending on anticholinergic properties. RESULTS: At baseline, 23.9% of women were taking at least one PIM and the mean ± SD ACB score was 1.41 ± 1.69. The most frequently reported PIMs were anticholinergics (15.2%), benzodiazepines (8.6%), and antispasmodics (8.0%). Over 10 years, PIM use increased for women with dementia (24.9-33.1%; P = .02) but remained fairly constant for women with MCI (23.9-23.0%; P = .84) and normal cognitive status (22.2-19.8%; P = .17). Mean ACB score increased significantly (P < .001) over time for all groups (dementia: 1.28-2.05; MCI: 0.98-1.66; normal: 0.99-1.48). CONCLUSION: PIM use and anticholinergic load in a community-dwelling population of older women was high, especially in women who later developed dementia. Future guidelines should limit PIM use and seek safer alternatives.
OBJECTIVES: To determine which older adults tend to receive potentially inappropriate medications (PIMs), how this may differ according to cognitive status, and how the trajectories of PIM use change over time. DESIGN: Ten-year longitudinal cohort study. SETTING: Three clinical sites in the United States. PARTICIPANTS: One thousand four hundred eighty-four community-dwelling women aged 75 and older. MEASUREMENTS: At follow-up, cognitive status was ascertained and classified as normal, mild cognitive impairment (MCI), or dementia. Beers 2003 criteria and other literature were used to identify PIMs from detailed medication inventory performed at three time points. Anticholinergic load was measured using the Anticholinergic Cognitive Burden Scale (ACB), which assigns medications a value from 0 to 3 depending on anticholinergic properties. RESULTS: At baseline, 23.9% of women were taking at least one PIM and the mean ± SD ACB score was 1.41 ± 1.69. The most frequently reported PIMs were anticholinergics (15.2%), benzodiazepines (8.6%), and antispasmodics (8.0%). Over 10 years, PIM use increased for women with dementia (24.9-33.1%; P = .02) but remained fairly constant for women with MCI (23.9-23.0%; P = .84) and normal cognitive status (22.2-19.8%; P = .17). Mean ACB score increased significantly (P < .001) over time for all groups (dementia: 1.28-2.05; MCI: 0.98-1.66; normal: 0.99-1.48). CONCLUSION:PIM use and anticholinergic load in a community-dwelling population of older women was high, especially in women who later developed dementia. Future guidelines should limit PIM use and seek safer alternatives.
Authors: Sabin S Egger; Andrea Bachmann; Nathalie Hubmann; Raymond G Schlienger; Stephan Krähenbühl Journal: Drugs Aging Date: 2006 Impact factor: 3.923
Authors: Carla Makhlouf Obermeyer; Michelle Schulein; Anita Hardon; Lynnette Leidy Sievert; Kim Price; Aldrin C Santiago; Olga Lazcano; Edward K Kirumira; Melissa Neuman Journal: Women Health Date: 2004
Authors: S Artero; M-L Ancelin; F Portet; A Dupuy; C Berr; J-F Dartigues; C Tzourio; O Rouaud; M Poncet; F Pasquier; S Auriacombe; J Touchon; K Ritchie Journal: J Neurol Neurosurg Psychiatry Date: 2008-05-01 Impact factor: 10.154
Authors: Kaycee M Sink; Joseph Thomas; Huiping Xu; Bruce Craig; Steven Kritchevsky; Laura P Sands Journal: J Am Geriatr Soc Date: 2008-04-01 Impact factor: 5.562
Authors: Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati Journal: Clin Interv Aging Date: 2009-06-09 Impact factor: 4.458
Authors: Noll L Campbell; Anthony J Perkins; Pamela Bradt; Sinem Perk; Ronald C Wielage; Malaz A Boustani; Daniel B Ng Journal: Pharmacotherapy Date: 2016-11-05 Impact factor: 4.705